• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pulmonary therapy. >Inhaler Operability and Patient Satisfaction Regarding Genuair? and Respimat? Inhalers for Chronic Obstructive Pulmonary Disease: A Randomized Crossover Study
【24h】

Inhaler Operability and Patient Satisfaction Regarding Genuair? and Respimat? Inhalers for Chronic Obstructive Pulmonary Disease: A Randomized Crossover Study

机译：关于Genuair的吸入器可操作性和患者满意度？和Respimat？慢性阻塞性肺疾病的吸入器：一项随机交叉研究

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IntroductionTiotropium via the Respimat? device, once daily, is a common treatment for patients with chronic obstructive pulmonary disease (COPD). Aclidinium via the Genuair? device, twice daily, is an alternative option. However, there are few studies comparing the two devices. We evaluated inhaler operability, patient satisfaction, and patient preference between Genuair and Respimat inhalers after 2?weeks of daily use. MethodsCOPD patients were randomly assigned to a Genuair or Respimat treatment group at Week 0, and were switched to the other treatment at the end of Week 2. The primary endpoint was the correct operation rate of the devices. The secondary endpoints included number of instructions needed to correctly operate the devices, number of technique errors, overall patient satisfaction, and willingness to continue using a device. ResultsFifty-four outpatients (mean age 74.3?±?10.1?years, 52 men) were enrolled, and all completed the study. The correct operation rate for the Genuair device was significantly higher than for the Respimat device (96.0?±?7.4% and 89.1?±?12.8%, respectively; p ConclusionOur findings suggest that the Genuair device is suitable for COPD patients, especially for those who are less adherent to treatment because of difficulties in inhaler handling, compared with the Respimat device. Trial RegistrationClinical Trials Registry (R000022399, UMIN000019373, 23/October/2015). FundingKyorin Pharmaceutical Co., Ltd.
机译：简介通过Respimat ？装置的噻托溴铵每天一次，是慢性阻塞性肺疾病（COPD）患者的常见治疗方法。另一种选择是通过Genuair ？设备每天两次进行Aclidinium。但是，很少有研究比较这两种设备。我们评估了每天使用2周后吸入器的可操作性，患者满意度以及Genuair和Respimat吸入器之间的患者偏好。方法COPD患者在第0周随机分配到Genuair或Respimat治疗组，并在第2周结束时切换至其他治疗。主要终点是设备的正确手术率。次要终点包括正确操作设备所需的指令数量，技术错误数量，总体患者满意度以及继续使用设备的意愿。结果共纳入54名门诊患者（平均年龄74.3±10.1岁，男52例），均完成了研究。 Genuair装置的正确手术率显着高于Respimat装置（分别为96.0％±7.4％和89.1％±12.8％; p结论）我们的发现表明Genuair装置适用于COPD患者，尤其是那些与Respimat装置相比，由于吸入器操作困难而对治疗依从性较差的人。试验注册临床试验注册中心（R000022399，UMIN000019373，23 / October / 2015）。资助人Kyorin Pharmaceutical Co.，Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号